نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - abacavir sulfate 702.78mg equivalent to abacavir 600 mg;  ; lamivudine 300mg - film coated tablet - active: abacavir sulfate 702.78mg equivalent to abacavir 600 mg   lamivudine 300mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry white 13b58894 purified talc silicified microcrystalline cellulose - antiretroviral combination therapy for the treatment of hiv in adults and adolescents from 12 years of age.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - entecavir monohydrate 0.53mg equivalent to 0.5 mg entecavir (anhydrous);   - film coated tablet - 0.5 mg - active: entecavir monohydrate 0.53mg equivalent to 0.5 mg entecavir (anhydrous)   excipient: crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1r-7003 purified water - entecavir is indicated for the treatment of chronic hbv infection in adults with evidence of active liver inflammation.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - entecavir monohydrate 1.06mg equivalent to 1 mg entecavir (anhydrous);   - film coated tablet - 1 mg - active: entecavir monohydrate 1.06mg equivalent to 1 mg entecavir (anhydrous)   excipient: crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1r-7003 purified water - entecavir is indicated for the treatment of chronic hbv infection in adults with evidence of active liver inflammation.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - domperidone maleate 12.72mg equivalent to domperidone 10 mg - tablet - 10 mg - active: domperidone maleate 12.72mg equivalent to domperidone 10 mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone purified water sodium laurilsulfate - treatment of acute symptoms of nausea and vomiting.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - pravastatin sodium 10mg;   - tablet - 10 mg - active: pravastatin sodium 10mg   excipient: croscarmellose sodium iron oxide yellow lactose monohydrate light magnesium oxide magnesium stearate microcelac 100 povidone - pravastatin is indicated: · in hypercholesterolemic patients without clinically evident coronary heart disease, as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. · for the reduction of elevated total and ldl-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. · as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease. · coronary artery disease: in patients with a history of either a myocardial infarction or unstable angina pectoris to reduce the risk for total mortality, chd death, recurrent coronary event (including myocardial infarction), need for myocardial revascularisation procedures, and need for hospitalisation. · cerebrovascular disease: in patients with a history of coronary artery disease (i.e. either a myocardial infarction or unstable angina pectoris) to reduce the risk of stroke or transient ischemic attacks (tias). · cardiac and renal transplantation: in patients receiving immunosuppressive therapy to improve survival in cardiac transplant patients and to reduce the risk of acute rejection in kidney transplant patients

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - pravastatin sodium 20mg;   - tablet - 20 mg - active: pravastatin sodium 20mg   excipient: croscarmellose sodium iron oxide yellow lactose monohydrate light magnesium oxide magnesium stearate microcelac 100 povidone - pravastatin is indicated: · in hypercholesterolemic patients without clinically evident coronary heart disease, as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. · for the reduction of elevated total and ldl-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. · as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease. · coronary artery disease: in patients with a history of either a myocardial infarction or unstable angina pectoris to reduce the risk for total mortality, chd death, recurrent coronary event (including myocardial infarction), need for myocardial revascularisation procedures, and need for hospitalisation. · cerebrovascular disease: in patients with a history of coronary artery disease (i.e. either a myocardial infarction or unstable angina pectoris) to reduce the risk of stroke or transient ischemic attacks (tias). · cardiac and renal transplantation: in patients receiving immunosuppressive therapy to improve survival in cardiac transplant patients and to reduce the risk of acute rejection in kidney transplant patients

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - pravastatin sodium 40mg;   - tablet - 40 mg - active: pravastatin sodium 40mg   excipient: croscarmellose sodium iron oxide yellow lactose monohydrate light magnesium oxide magnesium stearate microcelac 100 povidone - pravastatin is indicated: · in hypercholesterolemic patients without clinically evident coronary heart disease, as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. · for the reduction of elevated total and ldl-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. · as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease. · coronary artery disease: in patients with a history of either a myocardial infarction or unstable angina pectoris to reduce the risk for total mortality, chd death, recurrent coronary event (including myocardial infarction), need for myocardial revascularisation procedures, and need for hospitalisation. · cerebrovascular disease: in patients with a history of coronary artery disease (i.e. either a myocardial infarction or unstable angina pectoris) to reduce the risk of stroke or transient ischemic attacks (tias). · cardiac and renal transplantation: in patients receiving immunosuppressive therapy to improve survival in cardiac transplant patients and to reduce the risk of acute rejection in kidney transplant patients

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; ethylcellulose; titanium dioxide; povidone; macrogol 6000; hypromellose; purified talc; magnesium stearate; iron oxide red - for the treatment of hypertension.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 6000; povidone; ethylcellulose; crospovidone; purified talc; iron oxide red; titanium dioxide; hypromellose; lactose monohydrate - for the treatment of hypertension.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

viatris limited - efavirenz 600mg;  ; emtricitabine 200mg;  ; tenofovir disoproxil maleate 300mg equivalent to 245 mg tenofovir disoproxil - film coated tablet - active: efavirenz 600mg   emtricitabine 200mg   tenofovir disoproxil maleate 300mg equivalent to 245 mg tenofovir disoproxil excipient: colloidal silicon dioxide croscarmellose sodium hyprolose low-substituted hydroxypropylcellulose, lh 11 iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 85f540043 sodium metabisulfite - indicated for the treatment of hiv infected adults over the age of 18 years, alone or in combination with other antiretroviral agents.